BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 33197049)

  • 1. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
    Tefferi A; Gangat N; Pardanani A; Crispino JD
    Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloproliferative Neoplasms: A Contemporary Review.
    Tefferi A; Pardanani A
    JAMA Oncol; 2015 Apr; 1(1):97-105. PubMed ID: 26182311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
    Tefferi A; Vannucchi AM; Barbui T
    Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
    Coltro G; Loscocco GG; Vannucchi AM
    Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Risk Assessment in Myeloproliferative Neoplasms.
    Tefferi A; Vannucchi AM
    Mayo Clin Proc; 2017 Aug; 92(8):1283-1290. PubMed ID: 28778261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advances in the treatment of myelofibrosis].
    Takenaka K
    Rinsho Ketsueki; 2020; 61(9):1195-1204. PubMed ID: 33162516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA; Mesa RA; Hoffman R; Shammo JM
    Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelofibrosis Treatment Algorithm 2018.
    Tefferi A; Guglielmelli P; Pardanani A; Vannucchi AM
    Blood Cancer J; 2018 Jul; 8(8):72. PubMed ID: 30065290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.